Suppr超能文献

哈洛佩au连续性肢端皮炎对优化生物治疗的反应

Acrodermatitis continua of Hallopeau response to optimized biological therapy.

作者信息

Adas Alanoud, Dadban Ali, Arnault Jean-Philippe, Chaby Guillaume, Lok Catherine

机构信息

Department of Dermatology, Amiens University Hospital, Amiens.

出版信息

Dermatol Online J. 2019 Feb 15;25(2):13030/qt93s9w1p3.

Abstract

Acrodermatitis continua of Hallopeau, first described in 1890, is an uncommon variant of pustular psoriasis. It presents as a sterile pustular eruption of the tips of fingers and toes. The condition has a chronic, relapsing course and is often resistant to many anti-psoriatic therapies. In the following case, we present our experience of etanercept use in a 61-year-old man. Although initial therapy with high-dose etanercept achieved a rapid, sustained response and remission, the lesions relapsed a few months into a lower, maintenance dosage. This result prompted the use a second biotherapeutic agent ustekinumab, which resulted in complete remission, but required a higher dosage than recommended with reduced dosing intervals.

摘要

哈洛佩奥连续性肢端皮炎于1890年首次被描述,是脓疱型银屑病的一种罕见变体。它表现为手指和脚趾尖端的无菌性脓疱疹。该病病程慢性、易复发,且通常对多种抗银屑病疗法耐药。在以下病例中,我们介绍了一名61岁男性使用依那西普的经验。尽管初始使用高剂量依那西普治疗取得了快速、持续的反应和缓解,但在几个月后减至较低维持剂量时,皮损复发。这一结果促使使用第二种生物治疗药物乌司奴单抗,该药物导致了完全缓解,但所需剂量高于推荐剂量且给药间隔缩短。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验